New therapy developed by RTP biotech startup offers hope to sufferers of Crohn’s disease, colitis
The study, conducted by Gusto Global and UNC-Chapel Hill scientists, demonstrated that Gusto Global’s novel community of bacteria prevented and treated chronic immune-mediated colitis in “humanized” mouse models.
Read More
